DNA Immunization Against Amyloid beta 42 has High Potential as Safe Therapy for Alzheimer’s Disease as it Diminishes Antigen-Specific Th1 and Th17 Cell Proliferation

  • Doris Lambracht-Washington
  • Bao-Xi Qu
  • Min Fu
  • Larry D. AndersonJr
  • Olaf Stüve
  • Todd N. Eagar
  • Roger N. Rosenberg
Original Paper

Abstract

The pathogenesis of Alzheimer’s disease (AD) has been strongly associated with the accumulation of amyloid beta (Aβ) peptides in brain, and immunotherapy targeting Aβ provides potential for AD prevention. A clinical trial in which AD patients were immunized with Aβ42 peptide was stopped when 6% of participants showed meningoencephalitis, apparently due to an inflammatory Th1 immune response. Previously, we and other have shown that Aβ42 DNA vaccination via gene gun generates a Th2 cellular immune response, which was shown by analyses of the respective antibody isotype profiles. We also determined that in vitro T cell proliferation in response to Aβ42 peptide re-stimulation was absent in DNA Aβ42 trimer-immunized mice when compared to Aβ42 peptide-immunized mice. To further characterize this observation prospectively and longitudinally, we analyzed the immune response in wild-type mice after vaccination with Aβ42 trimer DNA and Aβ42 peptide with Quil A adjuvant. Wild-type mice were immunized with short-term (1–3× vaccinations) or long-term (6× vacinations) immunization strategies. Antibody titers and isotype profiles of the Aβ42 specific antibodies, as well as cytokine profiles and cell proliferation studies from this longitudinal study were determined. Sufficient antibody titers to effectively reduce Aβ42, but an absent T cell proliferative response and no IFNγ or IL-17 secretion after Aβ42 DNA trimer immunization minimizes the risk of inflammatory activities of the immune system towards the self antigen Aβ42 in brain. Therefore, Aβ42 DNA trimer immunization has a high probability to be effective and safe to treat patients with early AD.

Keywords

Amyloid beta Alzheimer’s disease Immunotherapy Gene gun Immune response Inflammation Th17 

References

  1. Aranami T, Yamamura T (2008) Th17 Cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 57(2):115–120PubMedCrossRefGoogle Scholar
  2. Bertram L, Tanzi RE (2004) The current status of Alzheimer’s disease genetics: what do we tell the patients? Pharmacol Res 50:385–396PubMedCrossRefGoogle Scholar
  3. DaSilva KA, Brown ME, McLaurin J (2009) Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer’s DNA vaccine. Vaccine 27(9):1365–1376PubMedCrossRefGoogle Scholar
  4. Davtyan H, Mkrtichyan M, Movsesyan N, Petrushina I, Mamikonyan G, Cribbs DH, Agadjanyan MG, Ghochikyan A (2009) DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther 17(2):261–271PubMedCrossRefGoogle Scholar
  5. Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurol 64:1563–1572CrossRefGoogle Scholar
  6. Ghochikyan A, Vasilevko V, Petrushina I, Movsesyan N, Babikyan D, Tian W, Sadzikava N, Ross TM, Head E, Cribbs DH, Agadjanyan MG (2003) Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol 33(12):3232–3241PubMedCrossRefGoogle Scholar
  7. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM (2005) Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64:1553–1562PubMedCrossRefGoogle Scholar
  8. Gocke A, Cravens PD, Ben L-H, Hussain RZ, Northrop SC, Racke MK, Lovett-Racke AE (2007) T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J Immunol 178:1341–1348PubMedGoogle Scholar
  9. Gurunathan S, Klinman DM, Seder RA (2000) DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18:927–974PubMedCrossRefGoogle Scholar
  10. Hardy J (1996) New insights into the genetics of Alzheimer’s disease. Ann Med 28:255–258PubMedCrossRefGoogle Scholar
  11. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356PubMedCrossRefGoogle Scholar
  12. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408:979–982PubMedCrossRefGoogle Scholar
  13. Kim HD, Jin JJ, Maxwell JA, Fukuchi K (2007a) Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer’s disease. Immunol Lett 15:30–38CrossRefGoogle Scholar
  14. Kim HD, Tahara K, Maxwell JA, Lalonde R, Fukuiwa T, Fujihashi K, Van Kampen KR, Kong FK, Tang DC, Fukuchi K (2007b) Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer’s disease. J Gene Med 9:88–98PubMedCrossRefGoogle Scholar
  15. Lambracht-Washington D, Qu BX, Fu M, Eagar TN, Stüve O, Rosenberg RN (2009) DNA beta-amyloid (1–42) trimer immunization for Alzheimer disease in a wild-type mouse model. JAMA 302(16):1796–1802PubMedCrossRefGoogle Scholar
  16. Maecker HT, Umetsu DT, DeKruyff RH, Levy S (1998) Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. J Immunol 161(12):6532–6536PubMedGoogle Scholar
  17. Monsonego A, Imitola J, Petrovic S, Zota V, Nemirovsky A, Baron R, Fisher Y, Owens T, Weiner HL (2006) Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 103:5048–5053PubMedCrossRefGoogle Scholar
  18. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408:982–985PubMedCrossRefGoogle Scholar
  19. Movsesyan N, Mkrtichyan M, Petrushina I, Ross TM, Cribbs DH, Agadjanyan MG, Ghochikyan A (2008a) DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. J Neuroimmunol 205(1–2):57–63PubMedCrossRefGoogle Scholar
  20. Movsesyan N, Ghochikyan A, Mkrtichyan M, Petrushina I, Davtyan H, Olkhanud PB, Head E, Biragyn A, Cribbs DH, Agadjanyan MG (2008b) Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine—a novel immunotherapeutic strategy. PLoS One 3(5):e2124PubMedCrossRefGoogle Scholar
  21. Murphy AC, Lalor SJ, Lynch MA, Mills KH (2010) Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun 24(4):641–651PubMedCrossRefGoogle Scholar
  22. Obar JJ, Lefrançois L (2010) Early events governing memory CD8+ T-cell differentiation. Int Immunol 22(8):619–625PubMedCrossRefGoogle Scholar
  23. O’Connor RA, Prendergast CT, Sabatos CA, Lau CWZ, Leech MD, Wraith DC, Anderton SM (2008) Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 181:3750–3754PubMedGoogle Scholar
  24. Qing Z, Sewell D, Sandor M, Fabry Z (2000) Antigen-specific T cell trafficking into the central nervous system. J Neuroimmunol 105(2):169–178PubMedCrossRefGoogle Scholar
  25. Qu B, Rosenberg RN, Li L, Boyer PJ, Johnston SA (2004) Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Arch Neurol 61:1859–1864PubMedCrossRefGoogle Scholar
  26. Qu B, Boyer PJ, Johnston SA, Hynan LS, Rosenberg RN (2006) Aβ42 gene vaccination reduces brain amyloid plaque burden in transgenic mice. J Neurol Sci 244:151–158PubMedCrossRefGoogle Scholar
  27. Qu B-X, Xiang Q, Li L, Johnston SA, Hynan LS, Rosenberg RN (2007) Aβ42 gene vaccine prevents Aβ42 deposition in brain of double transgenic mice. J Neurol Sci 260:204–213PubMedCrossRefGoogle Scholar
  28. Qu BX, Lambracht-Washington D, Fu M, Eagar TN, Stüve O, Rosenberg RN (2010) Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer’s disease. Vaccine 28(32):5280–5287PubMedCrossRefGoogle Scholar
  29. Redmond WL, Marincek BC, Sherman LA (2005) Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo. J Immunol 174(4):2046–2053PubMedGoogle Scholar
  30. Rosenberg RN (2005) Translational research on the way to effective therapy for Alzheimer’s disease. Arch Gen Psych 62:1186–1192CrossRefGoogle Scholar
  31. Saresella M, Calabrese E, Marventano I, Piancone F, Gatti A, Alberoni M, Nemni R, Clerici M (2011) Increased activity of Th-17 and Th-9 lymphocytes and a skewing of the post-thymic differentiation pathway are seen in Alzheimer’s disease. Brain Behav Immun 25(3):539–547PubMedCrossRefGoogle Scholar
  32. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173–177PubMedCrossRefGoogle Scholar
  33. Selkoe DJ (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192(1):106–113PubMedCrossRefGoogle Scholar
  34. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 14(8):837–842PubMedCrossRefGoogle Scholar
  35. Siffrin V, Radbruch H, Glumm R, Niesner R, Paterka M, Herz J, Leuenberger T, Lehmann SM, Luenstedt S, Rinnenthal JL, Laube G, Luche H, Lehnardt S, Fehling H-J, Griesbeck O, Zipp F (2010) In vivo imaging of partially reversible Th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 33(3):424–436PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Doris Lambracht-Washington
    • 1
    • 2
  • Bao-Xi Qu
    • 1
    • 2
  • Min Fu
    • 1
    • 2
  • Larry D. AndersonJr
    • 3
  • Olaf Stüve
    • 1
    • 4
  • Todd N. Eagar
    • 1
    • 5
  • Roger N. Rosenberg
    • 1
    • 2
  1. 1.Department of NeurologyUniversity of Texas Southwestern Medical CenterDallasUSA
  2. 2.Alzheimer’s Disease CenterUniversity of Texas Southwestern Medical CenterDallasUSA
  3. 3.Department of Internal MedicineUniversity of Texas Southwestern Medical CenterDallasUSA
  4. 4.VA North Texas Health Care System Medical Service Dallas VA Medical CenterDallasUSA
  5. 5.Department of PathologyUniversity of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations